Results 51 to 60 of about 98,010,213 (261)

Egg yolk anti-SARS-CoV-2 RBD IgY antibodies were measured after immunization.

, 2022
Egg yolk anti-SARS-CoV-2 RBD IgY antibodies were measured after immunization.
Umama A. Abdel-dayem (13822322), Jian Zheng (287758), David K. Meyerholz (8468712), Stanley Perlman (200056), Lok-Yin Roy Wong (13822328), Esam I. Azhar (8781383), Abby Odle (13822316), Ahmed M. Hassan (8893106), Arooj K. Qureshi (13822325), Alimuddin Zumla (65389), Sherif A. El-Kafrawy (8893100), Aymn T. Abbas (13822319)   +11 more
core   +1 more source

SARS-CoV-2 convalescence and hybrid immunity elicits mucosal immune responsesResearch in context

EBioMedicine, 2023
Summary: Background: Mucosal antibodies play a key role in the protection against SARS-CoV-2 infection in the upper respiratory tract, and potentially in limiting virus replication and therefore onward transmission. While systemic immunity to SARS-CoV-2
Olha Puhach, Mathilde Bellon, Kenneth Adea, Meriem Bekliz, Krisztina Hosszu-Fellous, Pascale Sattonnet, Nicolas Hulo, Laurent Kaiser, Isabella Eckerle, Benjamin Meyer   +9 more
doaj   +1 more source

Antibodies in the breastmilk of COVID-19 recovered women

BMC Pregnancy and Childbirth, 2022
Objective Human milk contains antibodies against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) which may serve as a protective factor through passive immunization in infants.
Paulina Szczygioł, Błażej Łukianowski, Katarzyna Kościelska-Kasprzak, Katarzyna Jakuszko, Dorota Bartoszek, Magdalena Krajewska, Barbara Królak-Olejnik   +6 more
doaj   +1 more source

Demographic characteristics of the sample that included 709 individuals who were tested for SARS-CoV-2 antibodies using the BioMedomics COVID-19 IgM/IgG Rapid Test and the Roche Elecsys Anti-SARS-CoV-2 assay.

, 2022
Demographic characteristics of the sample that included 709 individuals who were tested for SARS-CoV-2 antibodies using the BioMedomics COVID-19 IgM/IgG Rapid Test and the Roche Elecsys Anti-SARS-CoV-2 assay.
Reham Awni El Kahlout (12024456), Hiam Chemaitelly (439114), Abdullatif Al Khal (12024468), Laith J. Abu-Raddad (9262524), Riyazuddin Mohammad Shaik (11847037), Peter V. Coyle (6837260), Ali Nizar Latif (11570540), Einas Al Kuwari (12024471), Naema Hassan Abdulla Al-Mawlawi (12024459), Imtiaz Gilliani (12024462), Roberto Bertollini (9538620), Hamad Eid Al Romaihi (12024477), Mohamed H. Al-Thani (11847049), Soha R. Dargham (3613250), Nourah Younes (12024465), Gheyath K. Nasrallah (9200525), Zaina Al Kanaani (5018198), Mohamed G. Al Kuwari (12024474), Anvar Hassan Kaleeckal (11847034), Mohamed Ali Ben Hadj Kacem (11740494), Hadi M. Yassine (4675846), Patrick Tang (239534), Andrew Jeremijenko (11506565), Hanan F. Abdul Rahim (11847040)   +23 more
core   +1 more source

First Description of Serological Evidence for SARS-CoV-2 in Lactating Cows

Animals, 2022
Following the COVID-19 epidemic outbreak in Ariano Irpino, Campania region (Italy), we tested lactating cows for the presence of SARS-CoV-2 on a cattle farm at which, prior to the investigation, 13 of the 20 farmworkers showed COVID-19-like symptoms, and
Filomena Fiorito, Valentina Iovane, Ugo Pagnini, Claudia Cerracchio, Sergio Brandi, Martina Levante, Luisa Marati, Gianmarco Ferrara, Virginio Tammaro, Esterina De Carlo, Giuseppe Iovane, Giovanna Fusco   +11 more
doaj   +1 more source

Results of qualitative testing for SARS-CoV-2-specific antibodies in healthy individuals (N = 501), non-vaccinated and never diagnosed positively for SARS-CoV-2 infection.

, 2022
Results of qualitative testing for SARS-CoV-2-specific antibodies in healthy individuals (N = 501), non-vaccinated and never diagnosed positively for SARS-CoV-2 infection.
Amelia Kardaś (12041991), Krystyna Dąbrowska (315930), Kamil Barczyk (12042000), Aleksander Szymczak (7865159), Krzysztof Baniecki (12041979), Katarzyna Gembara (11603890), Zuzanna Kaźmierczak (7865156), Agnieszka Hoffmann (12041988), Artur Nahorecki (12041985), Wojciech Witkiewicz (674088), Aleksandra Pikies (12041982), Tomasz Klimek (12041997), Alina Szewczyk-Dąbrowska (12041994), Natalia Jędruchniewicz (7865168), Wiktoria Budziar (12041976), Marek Harhala (5873900)   +15 more
core   +1 more source

Dromedary camels as a natural source of neutralizing nanobodies against SARS-CoV-2

JCI Insight, 2021
The development of prophylactic and therapeutic agents for coronavirus disease 2019 (COVID-19) is a current global health priority. Here, we investigated the presence of cross-neutralizing antibodies against severe acute respiratory syndrome coronavirus ...
Lotfi Chouchane, Jean-Charles Grivel, Elmoubasher Abu Baker Abd Farag, Igor Pavlovski, Selma Maacha, Abbirami Sathappan, Hamad Eid Al-Romaihi, Sirin W.J. Abuaqel, Manar Mahmoud Ahmad Ata, Aouatef Ismail Chouchane, Sami Remadi, Najeeb Halabi, Arash Rafii, Mohammed H. Al-Thani, Nico Marr, Murugan Subramanian, Jingxuan Shan   +16 more
doaj   +1 more source

Nebulized mRNA‐Encoded Antibodies Protect Hamsters from SARS‐CoV‐2 Infection

Advanced Science, 2022
Despite the success of severe acute respiratory syndrome coronavirus‐2 (SARS‐CoV‐2) vaccines, there remains a clear need for new classes of preventatives for respiratory viral infections due to vaccine hesitancy, lack of sterilizing immunity, and for at ...
Daryll Vanover, Chiara Zurla, Hannah E. Peck, Nichole Orr‐Burks, Jae Yeon Joo, Jackelyn Murray, Nathan Holladay, Ryan A. Hobbs, Younghun Jung, Lorena C. S. Chaves, Laura Rotolo, Aaron W. Lifland, Alicia K. Olivier, Dapeng Li, Kevin O. Saunders, Gregory D. Sempowski, James E. Crowe Jr., Barton F. Haynes, Eric R. Lafontaine, Robert J. Hogan, Philip J. Santangelo   +20 more
doaj   +1 more source

Aptamer BC 007’s Affinity to Specific and Less-Specific Anti-SARS-CoV-2 Neutralizing Antibodies

, 2021
COVID-19 is a pandemic respiratory disease that is caused by the highly infectious severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Anti-SARS-CoV-2 antibodies are essential weapons that a patient with COVID-19 has to combat the disease. When
Peter Göttel, Annekathrin Haberland, Heike Nikolenko, Andre Dallmann, Johannes Müller, Hardy Weisshoff, Oxana Krylova   +6 more
core   +1 more source

SARS-CoV-2 neutralizing antibody development strategies

TURKISH JOURNAL OF BIOLOGY, 2020
In December 2019 a novel coronavirus was detected in Wuhan City of Hubei Province-China. Owing to a high rate of transmission from human to human, the new virus called SARS-CoV-2 differed from others by its unexpectedly rapid spread. The World Health Organization (WHO) described the most recent coronavirus epidemic as a global pandemic in March 2020 ...
Bertan Koray BALCIOĞLU, Melis DENİZCİ ÖNCÜ, Hasan Ümit ÖZTÜRK, Fatıma YÜCEL, Filiz KAYA, Müge SERHATLI, Hivda ÜLBEĞİ POLAT, Şaban TEKİN, Aylin ÖZDEMİR BAHADIR   +8 more
openaire   +3 more sources